Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
about
Targeted therapies and immunotherapy in non-small-cell lung cancerUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsMaking sense of big data in health research: Towards an EU action planA consensus statement on the gender perspective in lung cancer.Drug-sensitive FGFR3 mutations in lung adenocarcinoma.Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank.Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing.Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy.New insights into the role of EMT in tumor immune escape.Rapid Diagnosis of Lung Tumors, a Feasability Study Using Maldi-Tof Mass Spectrometry.Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?High-throughput detection of clinically targetable alterations using next-generation sequencing.First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumorsDabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.Resisting Resistance: Targeted Therapies in Lung Cancer.Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking statusMetastatic lung cancer in the age of targeted therapy: improving long-term survival.Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer.EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand.ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients.EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).MEDI 4736 (durvalumab) in non-small cell lung cancer.HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics.Lung Adenocarcinoma Survival in EGFR-Mutated African-Caribbean Patients: A Multicenter Study in the French West Indies.Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.Alectinib for treatment of ALK-positive non-small-cell lung cancer.Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.Alectinib for ALK-positive non-small-cell lung cancer.Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.Developments in pharmacotherapy for treating metastatic non-small cell lung cancer.
P2860
Q26738986-B3849355-A7CC-41C9-A032-8C102682C169Q28075291-D0D7BE4E-4C81-419C-BE48-1F5992A09A0CQ28597362-AA6595D2-7E5C-45E9-9B14-620A5D00AA78Q30240700-A5A5A257-886C-4CFA-B8F5-635CB3455643Q33564782-CB282110-2F4B-41F2-ABC8-6ECA701AF357Q33568536-76CE765C-D7A0-419C-B369-514775FDB0FBQ33591738-39BED47C-6D4C-403B-A2C0-08ACEF5486EAQ33599057-3A2D130B-A7A1-4713-84CE-F540ADC5E5F2Q33648808-EB4A218E-007D-4D88-BF5C-C186A29FB811Q33779727-847A7A93-AB81-42F6-B12E-C6E73E02A2D2Q33798605-3075C6D5-5F6E-4E67-91BC-5694F3D67D81Q33865965-6CD16003-A43C-4849-B660-A00DC9B9549DQ33869781-2B308305-1EFB-4642-AF5E-6E05A62327BDQ36030774-06698E4A-E3C7-474E-A3B7-9F5C5E213EC6Q36233903-4F7446BE-3C25-4E50-ACC7-0DA160F64641Q36305457-FBEC4C92-5C56-4221-89C5-3FD90C25677BQ36345358-A88138E6-0BAC-4299-BC2D-46FACE5EED06Q36675561-749FDB1E-FE56-48C5-8BA0-824F516FE574Q37193792-32B43EB6-F5FA-4B3D-B39F-F8D01E47C0C8Q37388238-648679EF-E8D8-49C3-A56E-59121BB2B354Q37564820-43E9ED23-C3E5-4B85-AD1B-B617EBB97F6FQ37584403-AD477048-A8D0-4011-BE10-498E8DFAB28FQ37690677-4A55ABD3-DB5D-4104-AA60-391CC0370E4AQ37702787-2C3491EF-6EDC-4DFB-A94E-96961AF82ECCQ38373208-567746B8-47B2-463A-9AE9-772C06F1BAD0Q38626147-B72D2323-A7B7-4D30-95DB-6640913C3B38Q38629823-3D3B1EBD-975D-4C27-9BE6-B69133A12530Q38650079-DA727D39-D0CF-4354-A667-BD7BBFF758EFQ38658050-3DE6719B-4F5E-46D6-BE94-0E3F1A7FD98AQ38661973-1EFE3A22-38E4-47DB-B76E-23567DFF1A70Q38684398-4C4AA07A-B863-4674-B764-6A1772A144FDQ38720804-E8737963-FD2B-41F4-8F7B-1F35533A10B8Q38792704-E3DB1317-AD97-4226-8DB1-371D548BFA98Q38805618-302C09DA-7DE7-4489-924C-9F53E5BFE166Q38816700-861EC048-01A9-4E70-9A41-B714BC62EF1BQ38846027-154A3728-2129-43B5-B362-A1CDD5BEBFD0Q38881066-CB76E33E-228A-4D5B-8552-4D24C4F6EBD7Q38991958-D188DCB3-DA8F-4412-BCBA-BB50A4060446Q38995524-1792F0B4-7C5A-4C03-8B39-549AE200F4B4Q39076364-36BD9F25-5F34-44CF-954E-1F708462E7A9
P2860
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Routine molecular profiling of ...... ve Thoracic Intergroup (IFCT).
@en
type
label
Routine molecular profiling of ...... ve Thoracic Intergroup (IFCT).
@en
prefLabel
Routine molecular profiling of ...... ve Thoracic Intergroup (IFCT).
@en
P2093
P50
P1433
P1476
Routine molecular profiling of ...... ve Thoracic Intergroup (IFCT).
@en
P2093
Alexandra Langlais
Antoinette Lemoine
Benjamin Besse
Bernard Milleron
Biomarkers France contributors
Didier Debieuvre
Fabienne Escande
Fabrice Barlesi
Franck Morin
Gérard Zalcman
P304
P356
10.1016/S0140-6736(16)00004-0
P407
P577
2016-01-14T00:00:00Z